miRNA-106 regulates negatively cholesterol efflux via the target gene ATP-binding cassette TransporterA1(ABCA1) as a therapeutic target for AD212 and may help regulate β-amyloid precursor protein (APP) expression in the brain and differentiate the neurons.213 Increasing APP protein levels cause high levels of Aβ and, consequently, synaptic dysfunction, neurodegeneration, and cognitive impairment.214. Here, APP is linked to Cognitive impairment.